Loading...
•
Mar 31, 2023
Biohaven Q1 2023 Earnings Report
Biohaven reported financial results for the first quarter ended March 31, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Key Takeaways
Biohaven reported a net loss of $70.5 million, or $1.03 per share, for the first quarter of 2023. The company is advancing its pipeline of therapies for neurological and neuropsychiatric diseases and expects to reach significant pipeline milestones in the coming periods.
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China).
Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy.
Taldefgrobep alfa granted Fast Track Designation in SMA.
Driving strong and consistent progress across six robust drug development platforms in 2023.
Biohaven
Biohaven
Forward Guidance
Biohaven expects to reach significant pipeline milestones in the coming periods.
Positive Outlook
- Initiate EEG study with BHV-7000 in the first half of 2023.
- Following Phase 1 study completion, Biohaven expects to initiate pivotal trials in patients with epilepsy and patients with bipolar disorder in the second half of 2023.
- Submit IND with BHV-7010 in epilepsy and mood disorders in the second half of 2023.
- Submit IND with BHV-2100 in chronic pain in the second half of 2023.
- Submit IND with BHV-1300 in the second half of 2023.